[go: up one dir, main page]

MX2021000566A - Anticuerpos anti-il36r. - Google Patents

Anticuerpos anti-il36r.

Info

Publication number
MX2021000566A
MX2021000566A MX2021000566A MX2021000566A MX2021000566A MX 2021000566 A MX2021000566 A MX 2021000566A MX 2021000566 A MX2021000566 A MX 2021000566A MX 2021000566 A MX2021000566 A MX 2021000566A MX 2021000566 A MX2021000566 A MX 2021000566A
Authority
MX
Mexico
Prior art keywords
antibodies
fragments
methods
human
il36r
Prior art date
Application number
MX2021000566A
Other languages
English (en)
Inventor
William Olson
Sokol Haxhinasto
Jeanette Fairhurst
Elena Garnova
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2021000566A publication Critical patent/MX2021000566A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona anticuerpos y fragmentos de unión a antígeno (por ejemplo, anticuerpos humanos) que se unen específicamente al receptor de IL-36 humano. Métodos para tratar o prevenir enfermedades mediadas por IL36R (por ejemplo, afecciones inflamatorias de la piel o del colon tales como psoriasis pustulosa palmoplantar, pustulosis palmoplantar, psoriasis pustulosa generalizada, colitis ulcerosa o IBD) mediante el uso de los anticuerpos y fragmentos que también se proporcionan junto con métodos para preparar los anticuerpos y fragmentos.
MX2021000566A 2018-07-16 2019-07-16 Anticuerpos anti-il36r. MX2021000566A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862698482P 2018-07-16 2018-07-16
US201962846989P 2019-05-13 2019-05-13
US201962866028P 2019-06-25 2019-06-25
PCT/US2019/041952 WO2020018503A2 (en) 2018-07-16 2019-07-16 Anti-il36r antibodies

Publications (1)

Publication Number Publication Date
MX2021000566A true MX2021000566A (es) 2021-06-23

Family

ID=67480435

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000566A MX2021000566A (es) 2018-07-16 2019-07-16 Anticuerpos anti-il36r.

Country Status (13)

Country Link
US (3) US11267893B2 (es)
EP (1) EP3823989A2 (es)
JP (1) JP7386224B2 (es)
KR (1) KR20210032401A (es)
CN (1) CN112513091B (es)
AU (1) AU2019306217B2 (es)
BR (1) BR112020027015A2 (es)
CA (1) CA3103531A1 (es)
IL (1) IL280013A (es)
MX (1) MX2021000566A (es)
PH (1) PH12020552178A1 (es)
SG (1) SG11202012360YA (es)
WO (1) WO2020018503A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017013080A (es) 2015-04-15 2018-02-09 Anaptysbio Inc Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r).
MX2021000566A (es) 2018-07-16 2021-06-23 Regeneron Pharma Anticuerpos anti-il36r.
MX2023000763A (es) 2020-07-17 2023-02-13 Boehringer Ingelheim Int Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrofilas.
WO2022026829A1 (en) 2020-07-30 2022-02-03 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity
CN116406295A (zh) * 2020-07-30 2023-07-07 安奈普泰斯生物有限公司 针对鱼鳞病的抗白介素36受体（il-36r）疗法
CN112094349B (zh) * 2020-11-04 2021-02-09 上海华奥泰生物药业股份有限公司 靶向于白介素36r的抗体及其制备方法和应用
WO2022127842A1 (zh) * 2020-12-17 2022-06-23 上海华奥泰生物药业股份有限公司 靶向il-17a和il-36r的双特异性抗体及其应用
WO2022150644A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for acne
WO2022150642A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa
WO2022166977A1 (zh) * 2021-02-08 2022-08-11 上海普铭生物科技有限公司 抗人il-36r抗体及其应用
WO2022187434A1 (en) * 2021-03-04 2022-09-09 Boehringer Ingelheim International Gmbh Methods for the treatment of gpp
JP2024512384A (ja) 2021-03-12 2024-03-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 汎発型膿疱性乾癬における抗ｉｌ－３６ｒ抗体による処置に関連したバイオマーカー
TW202317626A (zh) * 2021-06-18 2023-05-01 大陸商正大天晴藥業集團股份有限公司 抗il-36r抗體及其用途
WO2023285362A1 (en) * 2021-07-12 2023-01-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of il-36 inhibitors for the treatment of netherton syndrome
TW202323293A (zh) * 2021-10-29 2023-06-16 新加坡商創響私人有限公司 新型抗ｉｌ－３６ｒ抗體
CN115724975A (zh) * 2022-10-20 2023-03-03 江苏荃信生物医药股份有限公司 抗人白介素36受体单克隆抗体及其应用
CN116574189A (zh) * 2023-01-30 2023-08-11 北京智仁美博生物科技有限公司 针对人il-36r和/或人il-1r3的多种抗体及其用途
WO2024175031A1 (zh) * 2023-02-21 2024-08-29 江苏恒瑞医药股份有限公司 Il-36r结合蛋白及其医药用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5693489A (en) 1984-03-30 1997-12-02 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US6239268B1 (en) 1994-09-09 2001-05-29 Neurocrine Biosciences, Inc. Interleukin-1 type 3 receptors
EP0779923A2 (en) 1994-09-09 1997-06-25 Neurocrine Biosciences, Inc. Interleukin-1 type 3 receptors
CA2306455A1 (en) 1997-10-15 1999-04-22 Schering Corporation Human receptor proteins; related reagents and methods
US6326472B1 (en) 1997-10-15 2001-12-04 Schering Corporation Human receptor proteins; related reagents and methods
US20060003323A1 (en) 2000-03-01 2006-01-05 John Alsobrook Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6900016B1 (en) 2000-09-08 2005-05-31 Applera Corporation Polymorphisms in known genes associated with inflammatory autoimmune disease, methods of detection and uses thereof
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20030170630A1 (en) 2000-12-21 2003-09-11 Alsobrook John P. Proteins and nucleic acids encoding same
EP1729930A2 (en) 2004-04-01 2006-12-13 Sequenom, Inc. Methods for identifying risk of osteoarthritis and treatments thereof
US20080299042A1 (en) 2004-04-30 2008-12-04 Biogen Idec Ma Inc. Membrane Associated Molecules
EP1938104A2 (en) 2005-10-17 2008-07-02 Institute for Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
AR072999A1 (es) * 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US9023995B2 (en) 2011-11-16 2015-05-05 Boehringer Ingelheim International Gmbh Anti IL-36R antibodies
WO2014022540A1 (en) 2012-08-02 2014-02-06 Regeneron Pharmaceuticals, Inc. Multivalent antigen-binding proteins
ES2935257T3 (es) * 2013-03-15 2023-03-03 Univ Chicago Métodos y composiciones relacionadas con la actividad de las células T
MX2017013080A (es) 2015-04-15 2018-02-09 Anaptysbio Inc Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r).
US20180273627A1 (en) * 2017-03-27 2018-09-27 Boehringer Ingelheim International Gmbh Anti il-36r antibodies combination therapy
EP3765515A2 (en) 2018-03-14 2021-01-20 Boehringer Ingelheim International GmbH Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
JP7404256B2 (ja) 2018-03-14 2023-12-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 汎発性膿疱性乾癬の処置のための抗ｉｌ－３６ｒ抗体の使用
AU2019308205A1 (en) 2018-07-16 2020-11-19 Regeneron Pharmaceuticals, Inc. Non-human animal models of DITRA disease and uses thereof
MX2021000566A (es) 2018-07-16 2021-06-23 Regeneron Pharma Anticuerpos anti-il36r.

Also Published As

Publication number Publication date
PH12020552178A1 (en) 2021-06-28
SG11202012360YA (en) 2021-01-28
AU2019306217B2 (en) 2024-01-25
US20200017592A1 (en) 2020-01-16
KR20210032401A (ko) 2021-03-24
CN112513091A (zh) 2021-03-16
IL280013A (en) 2021-03-01
US12060428B2 (en) 2024-08-13
JP2021530229A (ja) 2021-11-11
NZ771227A (en) 2024-04-26
WO2020018503A3 (en) 2020-02-20
AU2019306217A1 (en) 2021-01-14
CN112513091B (zh) 2024-08-27
US20220162326A1 (en) 2022-05-26
WO2020018503A2 (en) 2020-01-23
CA3103531A1 (en) 2020-01-23
US11267893B2 (en) 2022-03-08
EP3823989A2 (en) 2021-05-26
JP7386224B2 (ja) 2023-11-24
BR112020027015A2 (pt) 2021-04-06
US20250011442A1 (en) 2025-01-09

Similar Documents

Publication Publication Date Title
PH12020552178A1 (en) Anti-il36r antibodies
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
CL2019002717A1 (es) Receptores de unión a antígeno mejorados.
PH12020551443A1 (en) Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
MX2016014210A (es) Anticuerpo que se une a fcrn para tratar enfermedades autoinmunes.
EA201891178A1 (ru) Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
EA201891983A1 (ru) Комбинированная терапия антителами к cd73
AR119295A1 (es) Moléculas de unión a antígeno ligantes de cea
MX2018012757A (es) Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
GEP20197034B (en) Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
PH12016501366A1 (en) Novel anti-baff antibodies
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
TN2016000046A1 (en) Bi-specific monovalent diabodies that are capable of binding cd123 and cd3, and uses therof
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
CR20210622A (es) Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
MX2022002682A (es) Anticuerpos anti-cd73.
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
MX2018010771A (es) Moleculas de union al transcrito 7 similar a inmunoglobulina (ilt7) y metodos de uso de las mismas.
JOP20220119A1 (ar) أجسام مضادة trem2 واستخداماتها
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
PH12019502694A1 (en) Anti-trkb antibodies
PH12018500445A1 (en) Use of anto-cd40 antibodies for treatment of lupus nephritis
EA201992317A1 (ru) Композиции и способы для диагностики рака легких
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
EA202092743A1 (ru) Антитела к il36r